About Nuo Therapeutics
Nuo Therapeutics is a publicly listed company based in Gaithersburg (United States) founded in 2001. Regenerative therapies for wound care and ulcers are developed. It operates in the Healthcare, Technology, and Aerospace, Defense & Maritime sectors. Nuo Therapeutics has raised $69.12 million across 18 funding rounds from investors including MidCap Financial, Anson Group and Maryland Department of Commerce. The company has 9 employees. Nuo Therapeutics has completed 2 acquisitions, including Aldagen and Angel Systems. Its chief executive, as recorded, is David Jorden. Nuo Therapeutics offers products and services including Aurix. Its focus areas include Aerospace, Maritime and Defense Tech, Military Tech, Healthcare Solutions and Therapeutic Devices. Its legal entity is Nuo Therapeutics, Inc. Its competitors include Imbed Biosciences, Cresilon and CellPhire; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2001 and based in Gaithersburg, United States, regenerative products targeting wound care, inflammation, and angiogenesis are developed by the company. Operations center on autologous platelet and plasma therapies, with the proprietary Aurix systema biodynamic hematogelapproved by the FDA for managing wounds and ulcers of varying types and severities. Focus remains on advancing therapies within the biotechnology sector.
- Annual Revenue$3.31 M (USD)142.72as on Dec 31, 2025
- Net Profit-$2.51 M (USD)-8.11as on Dec 31, 2025
- EBITDA-$2.36 M (USD)0.08as on Dec 31, 2025
- Total Equity Funding$69.12M (USD)
in 18 rounds
- Latest Funding Round$791.42K (USD), Post-IPO
Jul 2025
- InvestorsMidCap Financial
& 3 more
- Employee Count9
- Investments & AcquisitionsAldagen
& 1 more
Products & Services of Nuo Therapeutics
Nuo Therapeutics offers a comprehensive portfolio of products and services, including Aurix.
Biodynamic hematogel using patient's platelets for wound healing.
Funding Insights of Nuo Therapeutics
Nuo Therapeutics has successfully raised a total of $69.12M across 18 strategic funding rounds. The most recent funding activity was a Post-IPO round of $791.42 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.12M
- Total Rounds 18
- Last Round Post-IPO — $791,418
- First Round $3.65M
(Apr 2010)
- Investors Count 4
Latest 10 of 18 funding rounds of Nuo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $791,418 | Post-IPO | – | – | – |
| Sep 2024 | $849,125 | Post-IPO | – | – | – |
| May 2024 | $650,875 | Post-IPO | – | – | – |
| Dec 2023 | $962,500 | Post-IPO | – | – | – |
| Aug 2023 | $1.04M | Post-IPO | – | – | – |
| May 2018 | $500,000 | Post-IPO | – | – | – |
| May 2016 | $7.5M | Series C | – | – | – |
| Jun 2014 | $26M | Series C | – | – | – |
| Mar 2014 | $2M | Series B | – | – | |
| Dec 2013 | $3M | Series B | – | – | – |
4 investors in total: 4 institutional.
Investors in Nuo Therapeutics
Nuo Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include MidCap Financial, Anson Group and Maryland Department of Commerce.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
Diversified operations are conducted across multiple industries by Anson Group. | 2001 | anson-group.com | Saint Peter Port, Guernsey | |
Government agency focused on development of Maryland | 1884 | commerce.maryland.gov | Baltimore, United States | |
Investor details for Nuo Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nuo Therapeutics
2 people are tracked at Nuo Therapeutics (2 in leadership); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Paul Mintz | Leadership | |
David Jorden | CEO & Director | Leadership |
Complete people profiles for Nuo Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nuo Therapeutics
Nuo Therapeutics is a publicly listed company on the OTC with ticker symbol AURX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Feb 2017
- Listed onOTCMKTS: AURX
- Listed entityNuo Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS67059V2097
- Share price$1.30 · 2026-10-13
- Market capitalisation$63.0M
- EPS (diluted, trailing year)$-0.04
- Volume (last session)276
Financials of Nuo Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $3.3M | -$2.5M | -$2.4M |
| 2024 | $1.4M | -$2.3M | -$2.4M |
| 2023 | $608,520 | -$3.2M | -$3.1M |
| 2022 | $112,250 | -$3.2M | -$3.2M |
| 2021 | -$886,260 | -$90,670 |
Detailed financial statements for Nuo Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuo Therapeutics
Nuo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aldagen and Angel Systems.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Regenerative cell therapies for vascular disorders | aldagen.com | Durham, United States | 2001 | Feb 2012 | $40M | |
Provider of pest control services | angelsystems.com | Great Mills, United States | 1988 | Apr 2010 | •••• |
Complete acquisition details for Nuo Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Nuo Therapeutics
6 dated milestones of Nuo Therapeutics across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Nuo Therapeutics is founded.
- Acquisition Acquires Angel Systems.
- Funding First funding round of $3.6M.
- Acquisition Acquires Aldagen.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $791K.
Competitors of Nuo Therapeutics
Nuo Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Imbed Biosciences, Cresilon and CellPhire.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imbedbio.com | 2010 | Madison, United States | $22.7M | 35 | Nanotech-based wound care products are developed and provided. | |
| cresilon.com | 2010 | New York, United States | $106.67M | 73 | Developer of hemostatic products for wound care | |
| cellphire.com | 2006 | Rockville, United States | $25.3M | 62 | Platelet-based therapeutics for hemostasis and regenerative medicine are developed. |
Detailed competitors of Nuo Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nuo Therapeutics
The website of Nuo Therapeutics (nuot.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 51.7% vs previous month
Top companies in Cell Therapy
3 companies that operate in the same segment as Nuo Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nuo Therapeutics
Complete news archive for Nuo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuo Therapeutics
Nuo Therapeutics was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Nuo Therapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
David Jorden is the CEO of Nuo Therapeutics, as recorded in our data.
Nuo Therapeutics is a funded company, having raised a total of $69.12M across 18 funding rounds to date. The company's 1st funding round was a Series B of $3M, raised on Apr 2010.
Nuo Therapeutics has 9 employees.
Annual revenue of Nuo Therapeutics is $3.31M as on Dec 31, 2025.
Founded in 2001 and based in Gaithersburg, United States, regenerative products targeting wound care, inflammation, and angiogenesis are developed by the company. Operations center on autologous platelet and plasma therapies, with the proprietary Aurix systema biodynamic hematogelapproved by the FDA for managing wounds and ulcers of varying types and severities. Focus remains on advancing therapies within the biotechnology sector.
Nuo Therapeutics's top competitors include Imbed Biosciences, Cresilon and CellPhire.
Nuo Therapeutics offers Aurix.
Yes, Nuo Therapeutics is publicly traded on OTC under the ticker symbol AURX.
Nuo Therapeutics has made 2 acquisitions, including Aldagen, and Angel Systems.
Nuo Therapeutics has 4 investors. Key investors include MidCap Financial, Anson Group, Maryland Department of Commerce, and Aldagenholdings.